The prevalence of BRAF mutations, paucity of effective clinical approaches, and poor prognosis made BRAF-mutant metastatic disease ideal for adoption of novel small molecules such as vemurafenib, selectively targeting the BRAFV600E oncoprotein (8). The gene discussed is BRAF; the disease is metastatic neoplasm.